INTERSTITIAL LUNG DISEASES
Clinical trials for INTERSTITIAL LUNG DISEASES explained in plain language.
Never miss a new study
Get alerted when new INTERSTITIAL LUNG DISEASES trials appear
Sign up with your email to follow new studies for INTERSTITIAL LUNG DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug could slow lung damage in autoimmune patients
Disease control Recruiting nowThis study tests a new tablet called nerandomilast for adults with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. About 400 people who haven't improved on standard treatment will take either the drug or a placebo for at least 26 we…
Matched conditions: INTERSTITIAL LUNG DISEASES
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
BREAKTHROUGH: new drug aims to stop lung scarring before it starts
Prevention Recruiting nowThis study tests whether the drug nerandomilast can slow or prevent lung scarring in people aged 40 and older who have early lung changes and a family history of pulmonary fibrosis. About 80 participants will take either the drug or a placebo twice daily for up to 3 years. Doctor…
Matched conditions: INTERSTITIAL LUNG DISEASES
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Apr 30, 2026 15:48 UTC
-
New CT technique could spot hidden heart trouble in lung disease patients
Knowledge-focused Recruiting nowThis study uses advanced CT scans to look at both the lungs and heart in people with interstitial lung disease (ILD). The goal is to find early signs of heart damage, which is a common cause of death in ILD but often goes unnoticed until it's advanced. Researchers will enroll 123…
Matched conditions: INTERSTITIAL LUNG DISEASES
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:01 UTC